Drug intelligence / Profile preview

APTO-500

Development stage: Unknown
Lead developer: Aptose Biosciences
Modality: Small Molecules

Overview

APTO-500 is a small molecule MELK inhibitor developed by Aptose Biosciences. Its development was terminated in January 2016 as it no longer aligned with the company's strategic pipeline and vision.

Targets

MELK (Maternal embryonic leucine zipper kinase)

Beyond the preview

Go deeper on APTO-500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APTO-500.

Explore the full profile